multiple sclerosis Archives - Elixi International

17 April 2021

Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis

28 February 2020

Ofatumumab, the new potential first-choice treatment for Relapsing forms of Multiple Sclerosis

11 December 2019

First generics of Gilenya (fingolimod) capsules for the treatment of relapsing forms of multiple sclerosis (MS)